Urovant Sciences Ltd (NASDAQ:UROV) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 795,200 shares, a growth of 5.2% from the August 30th total of 755,700 shares. Based on an average daily volume of 37,200 shares, the days-to-cover ratio is presently 21.4 days. Approximately 10.9% of the shares of the stock are sold short.
NASDAQ:UROV opened at $9.46 on Friday. Urovant Sciences has a 12 month low of $4.05 and a 12 month high of $14.49. The stock has a 50 day moving average of $9.53 and a two-hundred day moving average of $8.54. The company has a current ratio of 6.20, a quick ratio of 6.20 and a debt-to-equity ratio of 0.29. The firm has a market cap of $284.59 million and a P/E ratio of -2.14.
Urovant Sciences (NASDAQ:UROV) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). On average, research analysts forecast that Urovant Sciences will post -4.02 earnings per share for the current year.
Several research firms have commented on UROV. ValuEngine upgraded Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Urovant Sciences in a research note on Monday, September 9th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $21.63.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Further Reading: Short Selling Stocks and Day Traders
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.